Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

als, Inc. and Alkermes, Inc., submitted a reply to a complete response letter issued in October 2010 by FDA regarding Bydureon™, an investigational medication for type 2 diabetes. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date of January 28, 2012.
  • The company submitted its reply to a complete response letter by FDA regarding Amyvid™, a molecular Positron Emission Tomography (PET) imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients.

  • The America Invents Act was signed into law, aligning new U.S. patent laws more closely with those from other countries and improving the global competiveness of U.S. innovator companies such as Lilly. The law will provide new advantages for U.S. inventors by streamlining the application process and addressing the backlog of current applications. This new law, which transitions the U.S. from a "first-to-invent" to a "first-inventor-to-file" system, is the most significant overhaul of the U.S. patent system in 175 years.

  • Third-Quarter Reported Results

    In the third quarter of 2011, worldwide total revenue was $6.148 billion, an increase of 9 percent compared with the third quarter of 2010. This 9 percent revenue growth was comprised of increases of 4 percent in volume and 4 percent due to the impact of foreign exchange rates. Price had a negligible impact on revenue growth, reflecting the loss of U.S. patent exclusivity for Gemzar® in November 2010. Total revenue in the U.S. increased 4 percent to $3.273 billion due to higher prices and increased volume. Total revenue outside the U.S. increased 15 percent to $2.874 billion due to the positive impact of foreign exchange rates and increased volume. Third-quarter 2011 total revenue was reduced by approximately $130 million due to the impact of U.S. health care reform.

    Gross margin increased 3.1 percent to $4.810 billion in the third quarte
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Lilly Declares Fourth-Quarter 2011 Dividend
    2. Lilly Announces Changes in Senior Management
    3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
    4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
    5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
    6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
    7. Lilly Health Channel Debuts on YouTube
    8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
    9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
    10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
    11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
    (Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
    (Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
    Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
    (Date:4/22/2014)... This news release is available in German . ... species are important intracellular signaling molecules, but their mode ... key aspects of cellular function and behavior, while at ... organelles, membranes and DNA. To analyze how redox signaling ... innovative optical microscopy technique has been developed jointly by ...
    (Date:4/22/2014)... 7 in 10 Americans support mandated coverage of birth ... researchers at the University of Michigan Health System. , ... of 18 at home, and adults with private or ... to support universal coverage of birth control medications, according ... of the American Medical Association ( JAMA ). ...
    (Date:4/22/2014)... alfa (trade name: NovoEight) has been approved since November ... patients with haemophilia A. In an early benefit assessment ... Market for Medicinal Products" (AMNOG), the German Institute for ... this new active ingredient offers an added benefit over ... findings, an added benefit of turoctocog alfa is not ...
    (Date:4/22/2014)... Cedars-Sinai stroke intervention researchers have been informed that ... of the National Institutes of Health, will award an ... clinical trial of an experimental drug for stroke. ... with recombinant tissue plasminogen activator, or rtPA the ... after onset. In laboratory rodent studies, 3K3A-APC, used in ...
    (Date:4/22/2014)... have found that the anxiety experienced with a ... impact a woman,s overall well-being. Their findings are ... was published online in the April 21, 2014 ... 40 to 60 percent of women who undergo ... experience a false-positive mammogram. Such mammograms require additional ...
    Breaking Medicine News(10 mins):Health News:Neuroimaging: Live from inside the cell 2Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:False-positive mammogram anxiety has limited impact on women's well-being 2
    ... cholesterol-lowering statins were significantly less likely to develop depression than ... MD, a physician at the San Francisco VA Medical Center ... San Francisco. The study was published electronically in the ... Whooley and her research team evaluated 965 heart disease patients ...
    ... News) -- Many young children from low-income families drink too ... and tooth decay, the American Academy of Pediatrics recommends children ... -- even 100 percent fruit juice -- each day. In ... on Children,s Health, however, it was found that about 50 ...
    ... c-MET expression in tumors., Invasion and metastasis were blocked ... are in late-stage clinical trials. PHILADELPHIA ... signaling inhibited tumor invasion and metastasis in a laboratory ... published in Cancer Discovery , the newest journal ...
    ... HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay News) -- ... in overweight and obese women as those of normal ... females, a group of reproductive experts said. During ... Federation of America and the Society of Family Planning, ...
    ... generate a lot of internal debris that can trigger the ... as lupus., Now Georgia Health Sciences University researchers report that ... from attacking a fetus also helps block development of these ... joints. , The findings point toward new treatment strategies ...
    ... THURSDAY, Feb. 23 (HealthDay News) Compared to other ... in elderly patients with dementia, a new study finds. ... in dementia care. "This data provides much-needed guidance and ... treating older demented patients," said Dr. Gisele Wolf-Klein, director ...
    Cached Medicine News:Health News:Statins linked with lower depression risk in heart patients 2Health News:Kids From Poorer Families Drink Too Much Juice: Poll 2Health News:Combined inhibition of VEGF and c-MET can decrease metastasis 2Health News:Contraceptives Work Well in Obese Women, But Hormone Levels Lower 2Health News:Contraceptives Work Well in Obese Women, But Hormone Levels Lower 3Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 3Health News:Certain Antipsychotics Up Risk of Death for Patients With Dementia: Study 2
    ... Established in 1939, AMT has become ... agencies for clinical laboratory practitioners and ... certification for Medical Technologists, Medical Laboratory ... Phlebotomy Technicians, Medical and Dental Assistants ...
    ... Proficiency Testing and Quality Assurance (for Waived ... assist POLs, clinics and small hospitals maintain ... accuracy of patient lab results and assist ... the opportunity to earn 12 P.A.C.E. Contact ...
    An enzyme linked immunosorbent assay (ELISA) for the detection and quantitationof RF IgG isotype in human serum of patients with rheumatoid arthritis....
    An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
    Medicine Products: